DoubleChecks

What was claimed

New Peptide named Petrelintide caused 9.2% weight-loss compared to 2% placebo, new study finds

Our verdict

Accurate

In the ZUPREME-2 phase 2b trial, petrelintide produced up to 9.2% mean body-weight reduction at week 28.

Combined assessment13 sourcesChecked Oct 14, 2026

Why this verdict

  • A new study finds these results.

    Misleading
    One assessment reached this conclusion

  • New peptide named petrelintide caused 9.2% weight-loss compared to 2% placebo, new study finds

    Verified
    All assessments reached this conclusion

  • The placebo group lost 2% of body weight.

    Verified
    One assessment reached this conclusion

Evidence reviewed

13 sources

Perplexity, Claude and ChatGPT sources are combined here.

biopharminternational.comfinance.yahoo.comground.newsyahoo.comtradingview.comhcplive.comroche.comeurekalert.orgsciencemediacentre.orgroche.com

Individual assessments

Assessment summary

The numerical result is supported by phase 2b topline data: up to 9.2% weight loss versus 2.0% with placebo at 28 weeks.biopharminternational.com finance.yahoo.com However, the result was reported by the companies and has not yet been peer reviewed, and the claim omits that the trial involved people with overweight or obesity and type 2 diabetes.biopharminternational.com

Claims reviewed

A new study finds these results.

Misleading
The results come from company-reported topline phase 2b data and have not been peer reviewed.biopharminternational.com The study population had overweight or obesity plus type 2 diabetes, so the result should not be generalized to all people seeking weight loss.

This claim may mislead readers without added context.

A new peptide named petrelintide caused up to 9.2% weight loss.

Verified
In the ZUPREME-2 phase 2b trial, petrelintide produced up to 9.2% mean body-weight reduction at week 28.biopharminternational.com finance.yahoo.com

The placebo group lost 2% of body weight.

Verified
The reported placebo-adjusted comparison was up to 9.2% mean weight loss with petrelintide versus 2.0% with placebo.biopharminternational.com finance.yahoo.com

Assessment summary

  • The claim accurately reflects the ZUPREME-2 trial results announced in October 2026.
  • Multiple authoritative sources confirm that petrelintide achieved up to 9.2% weight loss versus 2.0% placebo at 28 weeks.
  • The statement is factually accurate and appropriately specific about the study findings.

Claims reviewed

Petrelintide caused 9.2% weight-loss compared to 2% placebo

Verified
The ZUPREME-2 Phase 2b trial (220 participants, 28 weeks) demonstrated that petrelintide achieved up to 9.2% mean weight loss versus 2.0% with placebo biopharminternational.com globenewswire.com mugglehead.com. This is the highest-dose result from the efficacy estimand, with weight loss ranging from 7.4-9.2% across three treatment arms biopharminternational.com.

Assessment summary

  • Reported topline Phase 2 results show petrelintide produced mean weight loss around 9.2% versus ~2.0% for placebo in the published press releases and trial reports.
  • These figures come from randomized, placebo-controlled mid-stage trials and match the cited sources below roche.com via.ritzau.dk.

Claims reviewed

New peptide named petrelintide caused 9.2% weight-loss compared to 2% placebo, new study finds

Verified
Topline Phase 2 trial results reported mean weight loss up to 9.2% for petrelintide versus about 2.0% for placebo, as published in company trial releases and summaries roche.com via.ritzau.dk.

Check your own claim

Paste any statement, headline, or AI answer. Independent assessments check it and compare sources.

Share this result